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Diagnostic Accuracy of Multiparametric Magnetic Resonance
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Transperineal Template Saturation Prostate Biopsy for
the Detection and Characterization of Prostate Cancer
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Purpose: We evaluated the diagnostic accuracy of multiparametric magnetic
resonance imaging and multiparametric magnetic resonance imaging/trans-
rectal ultrasound fusion guided targeted biopsy against that of transperineal
template saturation prostate biopsy to detect prostate cancer.
Materials and Methods: We retrospectively analyzed the records of 415 men who
consecutively presented for prostate biopsy between November 2014 and
September 2016 at our tertiary care center. Multiparametric magnetic resonance
imaging was performed using a 3 Tesla device without an endorectal coil, followed
by transperineal template saturation prostate biopsy with the BiopSee fusion
system. Additional fusion guided targeted biopsy was done in men with a suspi-
cious lesion on multiparametric magnetic resonance imaging, defined as Likert
score 3 to 5. Any Gleason pattern 4 was defined as clinically significant prostate
cancer. The detection rates of multiparametric magnetic resonance imaging and
fusion guided targeted biopsy were compared with the detection rate of trans-
perineal template saturation prostate biopsy using the McNemar test.
Results: We obtained a median of 40 (range 30 to 55) and 3 (range 2 to 4) trans-
perineal template saturation prostate biopsy and fusion guided targeted biopsy
cores, respectively. Of the 124 patients (29.9%) without a suspicious lesion on mul-
tiparametric magnetic resonance imaging 32 (25.8%) were found to have clinically
significant prostate cancer on transperineal template saturation prostate biopsy. Of
the 291 patients (70.1%) with a Likert score of 3 to 5 clinically significant prostate
cancer was detected in 129 (44.3%) bymultiparametric magnetic resonance imaging
fusion guided targeted biopsy, in 176 (60.5%) by transperineal template saturation
prostate biopsy and in 187 (64.3%) by the combined approach. Overall 58 cases
(19.9%) of clinically significant prostate cancer would have been missed if fusion
guided targeted biopsy had been performed exclusively. The sensitivity of multi-
parametric magnetic resonance imaging and fusion guided targeted biopsy for
clinically significant prostate cancerwas 84.6% and 56.7%with a negative likelihood
ratio of 0.35 and 0.46, respectively.
Conclusions: Multiparametric magnetic resonance imaging alone should not be
performed as a triage test due to a substantial number of false-negative cases
with clinically significant prostate cancer. Systematic biopsy outperformed
fusion guided targeted biopsy. Therefore, it will remain crucial in the diagnostic
pathway of prostate cancer.
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TTSPB ¼ transperineal template
saturation prostate biopsy
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THE introduction of mpMRI has allowed for noninva-
sive localization of areas suspicious for PCa, in contrast
to traditional random sampling of the organ by TRUS
guided biopsy.1 Further technological advances led to a
combination of those methods by introducing mpMRI/
TRUS FTB platforms for targeted sampling of suspi-
cious regions identified on imaging.2,3
To date the reference tests in studies evaluating
the detection rate of FTB have been were standard
TRUS guided biopsy3 or whole gland histology.4
However, each of these methods have inherent dis-
advantages for histopathological correlation. Stan-
dard TRUS guided biopsy is inaccurate.5,6 Also, whole
gland specimens introduce selection bias by only
including patients diagnosed with PCa who qualify
for radical treatment, thus, excluding men with false-
negative biopsy results and low risk disease.7,8
It has been shown that FTB detects a higher
proportion of csPCa with fewer cores than standard
TRUS guided biopsies.3 These results opened a
debate on whether FTB alone without SBs might be
sufficient to detect csPCa.9,10
In our study we compared the performance of
mpMRI and mpMRI/TRUS fusion guided targeted
biopsy with TTSPB, a reference standard with bet-
ter representation of the disease in the prostate
gland than standard TRUS guided biopsy.11
PATIENTS AND METHODS
Study Design and Patient Selection
This retrospective analysis included all men who under-
went mpMRI followed by TTSPB with the BiopSee
fusion system between November 2014 and September
2016 at our academic tertiary care center. Patients pre-
viously treated for PCa were not included in study.
Criteria described by the START (Standards of Reporting
for MRI-Targeted Biopsy Studies) Consortium were fol-
lowed when reporting this study.12 The study was
approved by the local ethics committee.
Imaging
All patients underwent mpMRI with triplanar T2-weighted,
diffusion-weighted and dynamic contrast-enhanced se-
quences. In 68 patients (16%) mpMRI was performed else-
where. In 347 patients (84%)MRI was performed without an
endorectal coil on a whole body, 3 Tesla MAGNETOM
Skyra MRI system with 2 independent TimTX TrueShap
transmit channels (Siemens, Iselin, New Jersey). The pro-
tocol and the sequence parameters were in accord with
current international prostate MRI guidelines
(supplementary table 1, http://jurology.com/).13
All images where analyzed by board certified radiologists
who were not blinded to clinical information. A 5-point
Likert scale obtained from the clinical radiology reports
was used to designate ROIs as 1dhighly unlikely,
2dunlikely, 3dequivocal, 4dlikely and 5dhighly likely to
harbor clinically significant PCa. External mpMRIs without
a Likert score were reviewed by the local radiologist. This
Likert scale is a well established reporting scheme analo-
gous to PI-RADS (Prostate Imaging Reporting and Data
System) which has been used in several studies.7,14,15
Biopsy Protocol
Transperineal biopsies were performed by 3 urologists
with several years of experience with standard TRUS
guided biopsy. Prostates were biopsied according to the 20
Barzell zones. For optimal organ coverage needles were
placed using the BiopSee MRI/TRUS fusion biopsy sys-
tem. In patients with suspicious ROIs, defined as a Likert
score of 3 or greater on mpMRI, the lesions previously
Table 1
Overall Biopsy Na€ıve
Prior Biopsy
Neg Pos
No. pts 415 163 86 166
Median age at biopsy (IQR) 64 (58e69) 63 (57e68) 64 (60e69) 65 (58e70)
Median ng/ml prostate specific antigen (IQR) 6.7 (4.4e9.6) 5.8 (4.4e8.9) 8.6 (5.7e13.0) 6.5 (4.1e8.6)
Median ml prostate vol (IQR) 46.0 (32.5e62.5) 44.6 (34.0e60.1) 53.6 (41.0e70.0) 41.4 (30.0e60.1)
Median days MRI-biopsy (IQR) 30 (14e60) 31 (18e55) 39 (20e81.0) 26 (9e54)
No. highest Likert score (%):
No lesion or 1-2 124 (29.9) 49 (30.1) 36 (41.9) 39 (23.5)
3 76 (18.3) 36 (22.1) 18 (20.9) 22 (13.3)
4 126 (30.4) 52 (31.9) 18 (20.9) 56 (33.7)
5 89 (21.4) 26 (16.0) 14 (16.3) 49 (29.5)
No. Likert score 3 or greater ROIs (%):
0 124 (29.9) 49 (30.1) 36 (41.9) 39 (23.5)
1 201 (48.4) 81 (49.7) 31 (36.0) 89 (53.6)
2 71 (17.1) 27 (16.6) 14 (16.3) 30 (18.1)
3-5 19 (4.6) 6 (3.7) 5 (5.8) 8 (4.8)
Median Likert score 3 or
greater ROI max diameter (IQR)
11.0 (8.0e15.0) 11.0 (9.0e15.0) 10.0 (8.00e14.5) 12.0 (8.0e16.0)
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identified by the T2-weighted sequence were super-
imposed on the real-time TRUS images. Nonrigid fusion
was performed using the BiopSee MRI/TRUS fusion bi-
opsy system.16 Two to 4 additional cores were obtained
after completing systematic biopsies from each ROI.
Histopathology
Each single core that was taken was evaluated separately
by a uropathologist. Tumor length was measured in each
needle core and reported as the MCCL in mm. PCa was
defined as clinically significant in the presence of any
Gleason 4 pattern (GS 7 or greater). However, in the
absence of a clear consensus on clinical significance an
additional 4 definitions were also applied to enable
comparability with other studies. The definitions were 1)
GS 3 þ 4 or greater and MCCL 4 mm or greater, 2) GS 4 þ
3 or greater, 3) GS 4 þ 3 or greater, or MCCL 6 mm or
greater and 4) GS 3 þ 4 or greater, or MCCL 4 mm or
36.7%
20.4%
8.2% 8.2% 10.2%
26.5%
63.3%
79.6%
91.8% 91.8% 89.8%
73.5%
A n y  c a n c e r  
( P C a )
G S  ≥3 + 4  
( c s P C a )
G S  ≥3 + 4  a n d  
M C C L  ≥4 m m
G S  ≥4 + 3  G S  ≥4 + 3  o r  
≥6 m m  M C C L
G S  ≥3 + 4  o r  
≥4 m m  M C C L
Detectec by TTSPB No tumour detected
43.5%
25.8%
14.5% 9.7% 12.1%
30.6%
56.5%
74.2%
85.5% 90.3% 87.9%
69.4%
A n y  c a n c e r  
( P C a )
G S  ≥3 + 4  
( c s P C a )
G S  ≥3 + 4  a n d  
M C C L  ≥4 m m
G S  ≥4 + 3  G S  ≥4 + 3  o r  
≥6 m m  M C C L  
G S  ≥3 + 4  o r  
≥4 m m  M C C L
Detectec by TTSPB No tumour detected n=124
n=49
a
b
Figure 1. Diagnostic performance of transperineal template saturation prostate biopsy in patients in whom mpMRI revealed no ROI
interest with Likert score of 3 or greater. Detection rate is displayed for different definitions of clinical significance, and in all 124
patients (a) and 49 biopsy na€ıve patients (b).
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greater. The MCCL thresholds of 4 mm or greater and 6
mm were based on TTSPB studies defining the MCCLs
that provided more than 95% sensitivity to detect lesions
0.2 ml or greater and 0.5 ml or greater, respectively.7,17
Data Analysis and Statistics
We compared the performance of TTSPB, FTB and the
combination of TTSPB and FTB to detect PCa in patients
with 1 or more ROIs and a Likert score of 3 or greater. The
detection rate of csPCa is reported separately and for a
combination of the 2 techniques. IBM SPSS, version
22.0 was used for descriptive statistics. The McNemar test
was applied to compare the performance of different bi-
opsy strategies. The unit of accuracy assessment was 1
patient (ie a whole prostate).
Diagnostic accuracy measures of sensitivity, speci-
ficity, overall accuracy, positive predictive value, negative
predictive value and LRs along with the 95% CIs were
calculated with MedCalc, version 17.2. Interval LRs
were calculated as previously described18 to demonstrate
changes in pretest probability resulting from mpMRI and
FTB results. Tests were 2-sided and considered statisti-
cally significant at p <0.05.
RESULTS
A total of 415 treatment na€ıve patients underwent
mpMRI followed by TTSPB during the study period.
Table 1 ½T1lists clinical and radiographic characteris-
tics. GS was 6 and 7 in 90 (54.2%) and 76 patients
(45.8%), respectively, who had a prior biopsy posi-
tive for PCa. A median of 40 TTSPB cores (range 30
to 55) and 3 FTB cores (range 2 to 4) were taken.
10.5%
37.7%
34.2%
21.9%
29.8%
39.5%
13.2%
58.8%
50.9%
34.2%
45.6%
62.3%
12.3%
59.6%
51.8%
36.8%
48.2%
63.2%
G S  6 G S  ≥3 + 4     
( c s P C a )
G S  ≥3 + 4  a n d  
M C C L  ≥4 m m
G S  ≥4 + 3  G S  ≥4 + 3  o r   
≥6 m m  M C C L
G S  ≥3 + 4  o r   
≥4 m m  M C C L
FTB only TTSPB only CombinaƟon
11.0%
44.3%
38.5%
23.4%
33.0%
46.7%
15.1%
60.5%
49.8%
32.0%
45.0%
64.3%
12.0%
64.3%
55.7%
35.7%
49.8%
67.7%
G S  6 G S  ≥3 + 4     
( c s P C a )
G S  ≥3 + 4  a n d  
M C C L  ≥4 m m
G S  ≥4 + 3  G S  ≥4 + 3  o r   
≥6 m m  M C C L
G S  ≥3 + 4  o r   
≥4 m m  M C C L
FTB only TTSPB only CombinaƟon n=291
n=114
*
*
*
*
*
*
*
*
*
*
a
b
Figure 2. Detection rate of fusion guided targeted biopsy, transperineal template saturation prostate biopsy and combined approach in
patients in whom mpMRI revealed at least 1 ROI with Likert score of 3 or greater. Detection rate is shown for different definitions of
clinical significance and in all 291 patients (a) and 114 biopsy na€ıve patients (b). McNemar test was used to compare performance of
FTB vs TTSPB to detect clinically significant prostate cancer. Asterisk represents p <0.05.
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On mpMRI unsuspicious ROIs, defined as a Lik-
ert score of less than 3, were found in 124 men
(29.9%). Of these patients TTSPB detected any PCa
in 54 (43.5%) and csPCa in 32 (25.8%) (fig. 1½F1 , a).
When considering only biopsy na€ıve men, these
rates were only slightly lower at 36.7% and 20.4%,
respectively (fig. 1, b). Notably 4 patients (3.2%) had
a GS 8 and 1 (0.8%) had GS 10 despite the absence
of reported lesions on mpMRI.
In 291 patients (70.1%) at least 1 suspicious ROI
(Likert score 3 or greater) was reported on mpMRI.
TTSPB followed by FTB was successfully completed
in all of these 291 patients. Figure 2½F2 shows PCa the
detection rates of combined biopsy, and FTB and
TTSPB alone. The combined approach detected 222
PCa cases (76.3%), including 161 (55.3%) on FTB
alone vs 220 (75.6%) on TTSPB alone (p <0.001).
CsPCa was detected by the combined approach in
187 cases (64.3%), including 129 (44.3%) on FTB
alone vs 176 (60.5%) on TTSPB alone (p <0.001).
Thus, adding FTB to TTSPB resulted in addi-
tional detection of 11 patients (3.8%) while per-
forming FTB alone without TTSPB would have
missed 58 (19.9%) who harbored csPCa. Figure 3½F3
shows detection rates based on prior biopsy status
and Likert scores.
To address a possible confounding effect of the
FTB learning curve we compared the detection rate
of csPCa in the first 146 cases with that in the last
145. The incidence of cases missed by the FTB
approach decreased from 21.9% to 18.0%
(supplementary figure, http://jurology.com/).
We performed an additional subgroup analysis of
the detection of low and high risk PCa. GS 6 was
diagnosed in 35 patients (12%) by the combined
approach vs 32 (11%) by FTB and 44 (15%) by
TTSPB alone (p ¼ 0.148, table 2 ½T2). High risk tumors
(GS 8-10) were detected by the combined approach
in 59 men (20.3%) and TTSPB alone again delivered
performance superior to that of FTB alone (52 or
17.9% vs 36 or 12.4%, p ¼ 0.005). When performing
only FTB without TTSPB 3 patients (1%) with a GS
6 tumor and 23 (7.9%) with high risk PCa would
have been missed.
Tumor detection on mpMRI is a crucial step in
the diagnostic pathway of FTB. Therefore, we
considered 54 and 32 of the 124 men with negative
mpMRI but TTSPB detection of PCa and csPCa,
respectively, in the accuracy analysis and they
added to the FTB false-negative rate. For the spec-
ificity analysis cases diagnosed by FTB but not by
TTSPB were classified as false-positive findings
(supplementary table 2, http://jurology.com/). The
sensitivity of mpMRI and FTB for csPCa was 84.6%
415 consecutive mpMRIs
performed in men being evaluated
for PCa
163 biopsy
naïve
49 mpMRI
with Likert
score 1-2
10 csPCa
18 PCa
on TTSPB
114 mpMRI 
with Likert
score 3-5
67 csPCa
82 PCa
on TTSPB
43 csPCa
55 PCa
on FTB
86 with prior
negative biopsy
36 mpMRI 
with Likert
score 1-2
5 csPCa
8 PCa
on TTSPB
50 mpMRI 
with Likert
score 3-5
21 csPCa
26 PCa
on TTSPB
16 csPCa
18 PCa
on FTB
166 with prior
positive biopsy
39 mpMRI 
with Likert
score 1-2
17 csPCa
28 Pca
on TTSPB
127 mpMRI 
with Likert
score 3-5
88 csPCa
112 PCa
on TTSPB
70 csPCa
88 Pca
on FTB
318
10 32
1567 59
12
43 24
5
21
322
16 11
11
17
15
24
88
39
18
70
28
3
5
Figure 3. Detection rates of PCa and clinically significant PCa (Gleason score 7 or greater) based on prior biopsy status and mpMRI
Likert score.
Table 2. Gleason score differences (prognostic risk groups 1 to
5) detected by fusion targeted and transperineal template
saturation prostate biopsies
FTB Results
No. TTSPB Results
Total No.No Ca GS 6 GS 3 þ 4 GS 4 þ 3 GS 8 GS 9-10
No Ca 69 24* 21* 10* 3‡ 3‡ 130
GS:
6 2† 9 17* 2* 0‡ 2‡ 32
3 þ 4 0† 10† 35 9* 2‡ 5‡ 61
4 þ 3 0† 1† 7† 16 4‡ 4‡ 32
8 0‡ 0‡ 1‡ 2‡ 12 5* 20
9-10 0‡ 0‡ 2‡ 2‡ 1† 11 16
Totals 71 44 83 41 22 30 291
*Upgraded TTSPB prognostic risk group in relation to FTB.
†Upgraded FTB prognostic risk group in relation to FTB.
‡Upgraded to high risk category.
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and 56.7% with a negative LR of 0.35 and 0.46,
respectively. Table 3½T3 shows details of the accuracy
analysis. Supplementary table 3 (http://jurology.
com/) lists LRs based on Likert scores.
The mean  SD MCCL in patients with a suspi-
cious ROI was 5.3  4.1 and 6.0  4.2 mm for PCa
and csPCa, respectively. These means were signifi-
cantly higher than in patients without a suspicious
ROI on mpMRI, including 3.1 mm for PCa and 3.4
mm for csPCa (p ¼ 0.02). Figure 4½F4 shows the rela-
tionship between Likert scores and the presence of
csPCa. TTSPB outperformed FTB for all Likert
scores, including scores of 3, 4 and 5 (p ¼ 0.13,
<0.001 and 0.001, respectively).
There was a direct association between lesion size
on mpMRI and csPCa detection, including 29% for
ROI less than 5 mm, 33% for ROI 5 to 9 mm and 50%
for ROI 10 mm or greater (p ¼ 0.019, supplementary
table 4, http://jurology.com/). External imaging
revealed a comparable csPCa detection rate
(supplementary table 5, http://jurology.com/).
DISCUSSION
Technological advances in mpMRI have led to the
expectation that random biopsies of the prostate
would no longer be necessary and could be replaced
by targeted biopsies sometime in the near future, in
accordance with the development of diagnostic
pathways of other solid tumors.1 In the current
study we found that a significant number of men
with negative mpMRI harbored clinically significant
PCa. Furthermore, in the group with suspicious
mpMRI 58 csPCa cases (19.9%) would have been
missed without systematic biopsy (TTSPB). To our
knowledge this is the first study evaluating the role
of mpMRI and FTB based on highly extensive SB
with a median number of 40 cores as the refer-
ence test.
Assessing the diagnostic error of mpMRI remains
a major challenge. In previous investigations
addressing mpMRI sensitivity and specificity for
detecting PCa whole gland pathology (selection
bias)19e22 or standard TRUS guided biopsy (low
accuracy) served as a reference standard.23 This
may explain the wide 44% to 87% range of reported
sensitivity rates.1
Recently for the first time Ahmed et al assessed
the accuracy of mpMRI compared to TTSPB as the
reference test.7 Although scans were reported by
dedicated urological radiologists with special
training, mpMRI missed 12% of patients with GS 7
or greater disease. In the current study radiologists
with different years of experience with reading
prostate MRI reviewed the imaging, which might be
a reason for the lower sensitivity. However, the
Table 3. Sensitivity, specificity, overall accuracy, positive and negative predictive values, and positive and negative likelihood ratios
of detection of any prostate cancer and clinically significant prostate cancer (Gleason score 7 or greater) in all patients and in
subgroups based on prior biopsy status
% Sensitivity (95% CI) % Specificity (95% CI) % Accuracy (95% CI)
% Predictive Value (95% CI) Likelihood Ratio (95% CI)
Pos Neg Pos Neg
Detection of any PCa
Overall (415 pts):
mpMRI 80.3 (75e85) 49.7 (41e58) 69.9 (65e74) 75.6 (72e79) 56.5 (49e63) 1.59 (1.3e1.9) 0.40 (0.3e0.5)
Fusion targeted biopsy 58.4 (52e64) 97.2 (93e99) 71.6 (67e76) 97.6 (94e99) 54.6 (51e58) 20.6 (7.8e54.4) 0.43 (0.4e0.5)
Biopsy na€ıve (163 pts):
mpMRI 82.0 (73e89) 49.2 (36e62) 69.3 (62e76) 71.9 (66e77) 63.3 (51e74) 1.61 (1.2e2.1) 0.37 (0.2e0.6)
Fusion targeted biopsy 56.0 (46e66) 96.8 (89e100) 71.8 (64e79) 96.6 (88e99) 58.1 (53e63) 17.64 (4.5e69.8) 0.45 (0.4e0.6)
Neg prior biopsy (86 pts):
mpMRI 76.5 (59e89) 53.9 (39e68) 62.8 (52e73) 52.0 (53e61) 77.8 (64e87) 1.66 (0.2e2.4) 0.44 (0.2e0.8)
Fusion targeted biopsy 52.9 (35e70) 100 (93e100) 81.4 (72e89) 100 76.5 (69e82) e 0.47 (0.3e0.7)
Pos prior biopsy (166 pts):
mpMRI 80.0 (72e86) 42.3 (23e63) 74.1 (67e81) 88.2 (84e91) 28.2 (18e41) 1.39 (1.0e2.0) 0.47 (0.3e0.8)
Fusion targeted biopsy 61.4 (53e70) 92.3 (75e99) 66.3 (59e73) 97.7 (92e99) 30.8 (26e36) 7.99 (2.1e30.4) 0.42 (0.3e0.5)
Detection of clinically signiﬁcant PCa
Overall (415 pts):
mpMRI 84.6 (79e89) 44.4 (38e51) 64.6 (60e69) 60.5 (57e64) 74.2 (67e80) 1.52 (1.3e1.7) 0.35 (0.2e0.5)
Fusion targeted biopsy 56.7 (50e64) 94.7 (91e97) 75.7 (72e80) 91.5 (86e95) 68.5 (65e72) 10.68 (5.9e19.2) 0.46 (0.4e0.5)
Biopsy na€ıve (163 pts):
mpMRI 87.0 (77e94) 45.4 (35e56) 65.0 (57e72) 58.8 (54e64) 79.6 (68e88) 1.59 (1.3e2.0) 0.29 (0.2e0.5)
Fusion targeted biopsy 54.6 (43e66) 98.8 (94e100) 77.9 (71e84) 97.7 (86e100) 70.8 (66e76) 46.9 (6.6e332.8) 0.46 (0.4e0.6)
Neg prior biopsy (86 pts):
mpMRI 80.8 (61e93) 51.7 (38e65) 60.5 (49e71) 42.0 (34e50) 86.1 (73e93) 1.67 (1.2e2.3) 0.37 (0.2e0.9)
Fusion targeted biopsy 53.9 (33e73) 96.7 (88e100) 83.7 (74e91) 87.5 (63e97) 82.9 (76e88) 16.15 (4.0e66.1) 0.48 (0.3e0.7)
Pos prior biopsy (166 pts):
mpMRI 83.8 (75e90) 36.1 (24e49) 66.3 (59e73) 63.3 (55e71) 56.4 (43e69) 1.31 (1.1e1.6) 0.45 (0.3e0.8)
Fusion targeted biopsy 59.1 (49e69) 86.9 (76e94) 69.3 (62e76) 88.6 (80e94) 55.2 (49e61) 4.5 (2.3e8.8) 0.47 (0.4e0.6)
Transperineal template saturation prostate biopsy was referent and since tumor detection on mpMRI is crucial step in fusion targeted biopsy diagnostic pathway, 32 men
with false-negative mpMRI were included in fusion targeted biopsy accuracy analysis.
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detection of csPCa in 20.4% of biopsy na€ıve patients
with negative mpMRI shows that MRI invisible can-
cer is common outside of prospective clinical trials.
The false-negative rate remained significant at
greater than 10% even when considering only tumors
with a volume of 0.2 ml or greater and 0.5 ml or
greater. The negative LR of unsuspicious mpMRI was
0.35 in the entire cohort, which is considered to indi-
cate only a minor impact on the posttest probability.24
Evaluating the accuracy of FTB for detecting PCa
faces the same challenges as mpMRI in regard to
the reference test. Groups have investigated the
accuracy of FTB by comparing it whole gland his-
tology or standard TRUS guided biopsy.3 Consid-
ering the known high false-negative rate of up to
50% for standard TRUS guided biopsy7,8 the
frequently detected superiority of FTB is not sur-
prising.3 However, a clear trend toward lower FTB
accuracy was observed when a superior SB was
performed.
Siddiqui et al found FTB to be superior to stan-
dard TRUS guided biopsy with 16% more cases of
csPCa (GS 7 or greater) detected.9 In a similar study
Filson et al also found FTB to be superior to SB but
they detected only 13% more GS 7 or greater tumors
by replacing standard TRUS guided biopsy with
Artemis guided mapping biopsy.25 Since FTB
alone would have missed 60 cases of csPCa, the in-
vestigators concluded that the most accurate results
were achieved by combining FTB and software
guided SB.
Radtke26 and Hansen27 et al compared FTB to
software guided TTSPB with a median of 24 cores.
While the first study showed no advantage of any
approach for detecting csPCa, the latter investiga-
tion revealed the superiority of TTSPB with an
overall 9% higher detection rate (p <0.001). We
could further confirm this trend. With a median of
40 cores our software guided TTSPB detected 19.9%
more csPCa cases than FTB alone in an unselected
19.4%
34.6%
69.2%
14.7%
33.3% 30.6%
61.5%
92.3%
30.6%
63.5%
92.3%
S C O R E  1  ( N = 3 4 ) S C O R E  2  ( N = 1 5 ) S C O R E  3  ( N = 3 6 ) S C O R E  4  ( N = 5 2 ) S C O R E  5  ( N = 2 6 )
FTB only TTSPB only CombinaƟon
21.1%
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Figure 4. Diagnostic performance of fusion guided targeted biopsy, transperineal template saturation prostate biopsy and combined
approach classified by highest Likert score on mpMRI. Detection rate is shown in all 415 patients (a) and 163 biopsy na€ıve patients (b).
McNemar test was used to compare performance of FTB vs TTSPB to detect clinically significant prostate cancer. ns, nonsignificant.
Asterisk indicates p <0.05.
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and consecutive group of men being evaluated for
PCa. With a negative LR of 0.6, FTB could not
sufficiently lower the posttest probability to rule out
PCa.24
One could argue that this poorer performance
was due to poor execution of the FTB technique.
Recently reported detection rates of csPCa based
on software based fusion were 16%, 33% and 69%
in the study by Filson et al,25 and 13%, 35% and
74% in the study by Mariotti et al28 for scores of 3,
4 and 5, respectively, for lesions detected by
mpMRI. With a slightly higher detection rate of
21%, 38% and 73%, respectively, the performance
of FTB in the current study is comparable to that
in the other reports, validating our FTB tech-
nique. Therefore, we do not attribute the better
performance by TTSPB than by FTB to low accu-
racy of our FTB technique but rather to the
significantly higher detection rate of software
guided TTSPB compared to other SB techniques
reported to date.
Yet FTB remains an error prone process. Radtke
et al evaluated the diagnostic yield of mpMRI and
FTB using whole gland histology.19 They found that
FTB performed less accurately to detect csPCa since
it missed lesions that were accurately detected by
mpMRI. A similar trend was observed in the current
study with significantly higher sensitivity of
mpMRI compared with FTB (csPCa detection 84.6%
vs 56.7%).
It was believed that the inaccuracy of the FTB
method29 could be overcome by an in bore MRI
guided biopsy technique using a real-time image of
the patient prostate. However, a systematic review
did not show a higher detection rate for csPCa than
for FTB despite the greater technical effort and
higher costs.30 Therefore, we believe that at the
moment no targeted biopsy method can reliably and
constantly place the needle in the ROI defined by
imaging and achieve the higher accuracy of mpMRI
in the detection of csPCa.
Limitations of this investigation are its retro-
spective nature and the heterogeneous popula-
tion of men, including patients undergoing initial
or repeat biopsy, patients on active surveillance
or patients being evaluated for focal therapy.
However, a subgroup analysis of biopsy na€ıve
patients revealed a similar detection rate.
Furthermore, multiple radiologists not blinded to
clinical data with different years of experience
with reading prostate mpMRIs reported the ex-
aminations using a Likert score instead of the
more common PI-RADS score. In contrast, either
could also be considered a strength of the study
since it more realistically reflects real-world
clinical circumstances. Finally, we cannot rule
out that cancers missed by TTSPB and prostate
swelling during fusion compromised the FTB
detection rate.
CONCLUSIONS
Based on our analysis mpMRI alone should not be
performed as a triage test in men being evaluated
for suspected PCa due to a substantial number of
false-negative csPCa results. SB using TTSPB out-
performed software based FTB. Therefore, it will
remain crucial in the diagnostic pathway of PCa
until new modalities can provide reliable accuracy
in daily clinical practice.
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EDITORIAL COMMENTS
In this clinically relevant study the authors
assessed the diagnostic accuracy of mpMRI and
FTB compared to TTSPB in a cohort of 415 consec-
utive patients.
Beyond the study limitations which are clearly
acknowledged by the authors, such as its retro-
spective nature and heterogenous population, the
current study highlights the limitations of mpMRI
with 25.8% of negative mpMRI cases harboring
csPCA. Indeed, 19.9% of csPCa cases would have
been missed if FTB alone has been performed,
leading the authors to question the reliability of
the FTB alone approach.
Of patients with suspicious mpMRI (Likert
score 3 to 5) FTB detected csPCa in 44.3%, TTSPB
detected csPCa in 60.5% and the combined
approach detected csPCa in 64.3%. TTSPB out-
performed FTB alone while the combined strategy
appeared to be best, as supported by other
contemporary studies (reference 27 in article).
Combined FTB and TTSPB biopsies provided
more complete and reliable sampling (reference 26
in article).
Currently mpMRI is limited in the detection of
Gleason pattern 3 and possibly also in the detec-
tion of cribriform pattern 4.1 This is of the upmost
importance in the context of active surveillance
and focal therapy strategies that cannot rely on
sampling an index lesion, potentially missing
contralateral, multifocal and even clinically sig-
nificant disease.
Jose L. Domı´nguez-Escrig
Servicio de Urologı´a
Fundacion Instituto Valenciano de Oncologı´a
Valencia, Spain
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Mortezavi et al provide an important contribution in
this study evaluating the accuracy of mpMRI and
FTB compared to a TTSPB reference standard. All
415 men underwent mpMRI and TTSPB. The 291
men (70%) with abnormal MRI also underwent
FTB. This study nicely complements PROMIS
(Prostate MRI Imaging Study) by evaluating MRI
and FTB instead of conventional TRUS biopsy
(reference 7 in article).
The study has 3 particularly notable findings. 1)
Of the men with a normal mpMRI 26% had csPCa.
This exceeds the 11% reported in PROMIS (refer-
ence 7 in article). To our knowledge it is unknown
which study more accurately reflects real-world
MRI performance. 2) FTB alone would have missed
csPCa in 58 men (20%) with an abnormal MRI.
TTSPB over diagnosed 12 men with Gleason 6
cancer but found an additional 16 men with Gleason
8-10. 3) A strategy in which only men with an
abnormal MRI underwent biopsy (FTB without
systematic sampling) would have missed csPCa in
90 men (22%). This is a strong argument that this
approach may be ill advised despite its attractive-
ness in principle.
Instead, we suggest considering clinical infor-
mation along with MRI to improve decision making
about biopsy1 and combining FTB with systematic
biopsy to maximize csPCa detection (reference 25 in
article).
Nancy N. Wang and Geoffrey A. Sonn
Department of Urology
Stanford University School of Medicine
Stanford, California
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